19 results on '"Duan, T."'
Search Results
2. Uterine Massage to Reduce Blood Loss After Vaginal Delivery.
- Author
-
Chen, M., Chang, Q., Duan, T., He, J., Zhang, L., and Liu, X.
- Published
- 2014
- Full Text
- View/download PDF
3. Three-Year Outcomes in Patients with Delayed Graft Function in Phase III Studies of Belatacept Vs Cyclosporine in Kidney Transplantation (BENEFIT and BENEFIT-EXT).
- Author
-
Charpentier, B., Vincenti, F., Rice, K., Budde, K., Campistol, J., Duan, T., Pupim, L., and Florman, S.
- Published
- 2012
- Full Text
- View/download PDF
4. Four-Year Outcomes by Donor Type from the Long-Term Extension of the Belatacept BENEFIT and BENEFIT-EXT Studies.
- Author
-
Durrbach, A., Medina Pestana, J., Becker, T., Grinyo, J., Lang, P., Garcia, V. D., Agarwal, M., Duan, T., and Florman, S.
- Published
- 2012
- Full Text
- View/download PDF
5. Long-Term Extension of the Belatacept BENEFIT-EXT Study: Results at Month 48.
- Author
-
Grinyo, J., Florman, S., Medina Pestana, J. O., Del Carmen Rial, M., Muehlbacher, F., Durrbach, A., Vincenti, F., Harler, M. B., Duan, T., and Rostaing, L.
- Published
- 2012
- Full Text
- View/download PDF
6. Long-Term Extension of the Belatacept BENEFIT Study: Results at Month 48.
- Author
-
Vincenti, F., Charpentier, B., Rostaing, L., Reyes-Acevedo, R., Massari, P., Vitko, S., Alberu, J., Harler, M. B., Duan, T., and Larsen, C.
- Published
- 2012
- Full Text
- View/download PDF
7. BENEFIT-RISK PROFILE OF THE BELATACEPT LI REGIMEN AT 2 YEARS IN EBV(+) KIDNEY TRANSPLANT RECIPIENTS.
- Author
-
Vincenti, F., Grinyo, J., Larsen, C., Pestana, J. O.m., Vanrenterghem, Y., Duan, T., Agarwal, M., and Charpentier, B.
- Published
- 2010
- Full Text
- View/download PDF
8. OUTCOMES AS A FUNCTION OF DONOR CRITERIA FROM A PHASE III STUDY OF BELATACEPT VS CYCLOSPORINE IN KIDNEY TRANSPLANTATION (BENEFIT-EXT).
- Author
-
Florman, S., Durrbach, A., Larsen, C., Pestana, J. M., Vanrenterghem, Y., Vincenti, F., Block, A., Garg, P., Copley, B., Duan, T., and Grinyó, J. M.
- Published
- 2010
- Full Text
- View/download PDF
9. Influence of Job Burnout on Decision-Making and Coping With Stress Among Nurses.
- Author
-
Gao Y, Liu J, Liu J, and Duan T
- Subjects
- Humans, Surveys and Questionnaires, Burnout, Psychological, Adaptation, Psychological, Burnout, Professional, Occupational Stress, Nurses
- Abstract
Job burnout is highly prevalent among health care workers. This study determined the effect of job burnout on decision-making and coping with stress among nurses. Two hundred seventy-seven nurses in Xijing Hospital were investigated using the Job Burnout Scale, Decision Scale, and Simple Stress Coping Style Scale. The total score of job burnout was 107.8 ± 16.479 (severe burnout) and clinical decision-making consciousness was 123.75 ± 16.094 (moderate decision-making consciousness). No statistical differences existed in different gender samples (P > .05). Burnout and clinical decision-making awareness of clinical nurses were stronger than nursing interns and regular trainee nurses, but the occupational pressure of nursing interns was the highest (P < .05). Marital status also showed significant differences in job burnout; unmarried nurses were more prone to burnout (P < .05). In conclusions, burnout is a serious issue among nurses, which is closely related with clinical decision-making awareness, negative coping, and occupational stress. Nurse identity and marital status had significant effects on burnout., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
10. Prenatal Maternal Bereavement and Its Association With Intellectual Disability in the Offspring.
- Author
-
Su X, Yu Y, Meng L, Duan T, Zhao Y, László KD, Valdimarsdóttir UA, Hua J, and Li J
- Subjects
- Adolescent, Child, Cohort Studies, Denmark epidemiology, Female, Grief, Humans, Male, Pregnancy, Registries, Risk Factors, Bereavement, Intellectual Disability epidemiology, Prenatal Exposure Delayed Effects epidemiology
- Abstract
Objective: This study aimed to examine the association of a mother's loss of a close relative before or during pregnancy with intellectual disability (ID) in the offspring., Methods: We performed a nationwide population-based cohort study based on Danish national registries. All live-born singletons born in Denmark during the 1978-2016 period (n = 2,216,601) were followed up starting from birth to 38 years of age. Log-linear Poisson regression was used to estimate the association between maternal bereavement (the death of an older child, a partner, or a parent 1 year before or during pregnancy) and the risk of ID in the offspring., Results: Maternal bereavement during or before pregnancy was associated with an increased risk of ID (incidence rate ratio [IRR] = 1.15; 95% confidence interval [CI] = 1.04-1.28). The risk of ID was increased by 27% when maternal bereavement occurred during pregnancy (IRR = 1.27; 95% CI = 1.08-1.49). When stratifying on the child's sex, we also observed an increased risk of ID associated with maternal bereavement during pregnancy both for male (IRR = 1.25; 95% CI = 1.02-1.53) and for female (IRR = 1.31; 95% CI = 1.02-1.69), respectively. The IRRs for unnatural death of a relative were also elevated (IRR = 1.22; 95% CI = 0.91-1.64) in general, although the difference was not statistically significant., Conclusions: Our findings suggest that prenatal stress due to maternal loss of a close relative may increase the risk of offspring's ID of both sexes, in particular when the loss happened during pregnancy., (Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Psychosomatic Society.)
- Published
- 2021
- Full Text
- View/download PDF
11. Efficacy and safety of elemene combined with chemotherapy in advanced gastric cancer: A Meta-analysis.
- Author
-
Liu Y, Chen L, Zhang R, Chen B, Xiang Y, Zhang M, Huang X, Zhang W, Chen X, Pan T, Yan L, Jin T, Liu S, Feng J, Duan T, Xie T, Lin S, and Sui X
- Subjects
- Humans, Randomized Controlled Trials as Topic, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Drugs, Chinese Herbal therapeutic use, Sesquiterpenes therapeutic use, Stomach Neoplasms drug therapy
- Abstract
Background: Elemene is a natural compound extracted from Zingiberaceae plants, and is used in various cancer. However, the efficacy and safety elemene combined with chemotherapy in advanced gastric cancer (GC) are lack of systematic assessment., Methods: we searched the PubMed, EMBASE, Web of Science, Cochrane Library, China Academic Journals (CNKI), Chinese Science and Technology Journals (CQVIP) and Chinese Biomedical Literature databases. Randomized controlled trials (RCTs) comparing elemene plus chemotherapy with chemotherapy alone in participants with advanced GC and reporting at least one of the following outcomes were selected and assessed for inclusion. JADAD scale was used to assess the quality. Data was screened and extracted by two independent investigators. The primary clinical outcome was overall response rate (ORR); the secondary outcomes were quality of life (QOL) and adverse events (AEs). Analysis was performed using Review Manager 5.3., Results: Sixteen RCTs matched the selection criteria, which reported on 969 subjects. Risk ratios (RR) and corresponding 95% confidence intervals (CIs) were pooled for ORR, life quality based on KPS, and risk of AEs. Compared to chemotherapy alone, elemene combined with chemotherapy in the treatment of GC may increase the efficiency of ORR(RR: 1.41; 95% CI: 1.23-1.60; P < .0001), improve their life quality based on KPS (RR: 1.84; 95% CI: 1.45-2.34; P < .00001), and reduce the adverse reactions, including leukopenia(RR: 0.73; 95% CI: 0.62-0.85; P < .00001), neutropenia (RR: 0.75; 95% CI: 0.60-0.95; P = .02), anemia (RR: 0.76; 95% CI: 0.60-0.95; P = .02), thrombocytopenia (RR: 0.56; 95% CI: 0.43-0.73; P < .00001). Nausea and vomiting (RR: 0.84; 95% CI: 0.84-1.07; P = .39), diarrhea (RR: 0.69; 95% CI: 0.41-1.15; P = .15), neurotoxicity (RR: 0.77; 95% CI: 0.59-1.00; P = .05) and hepatic dysfunction (RR: 0.95; 95% CI: 0.58-1.54; P = .83) were similar between two groups., Conclusions: Elemene may have the potential to improve the efficacy and reduce the AEs of chemotherapy for gastric cancer. However, the long-term, high-quality researches with a large sample size in different populations are required.
- Published
- 2020
- Full Text
- View/download PDF
12. Clinical Value of Predicting Individual Treatment Effects for Intensive Blood Pressure Therapy.
- Author
-
Duan T, Rajpurkar P, Laird D, Ng AY, and Basu S
- Subjects
- Aged, Antihypertensive Agents adverse effects, Female, Humans, Hypertension diagnosis, Hypertension physiopathology, Male, Middle Aged, Randomized Controlled Trials as Topic, Risk Assessment, Risk Factors, Treatment Outcome, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Data Mining, Hypertension drug therapy, Machine Learning
- Abstract
Background: The absolute risk reduction (ARR) in cardiovascular events from therapy is generally assumed to be proportional to baseline risk-such that high-risk patients benefit most. Yet newer analyses have proposed using randomized trial data to develop models that estimate individual treatment effects. We tested 2 hypotheses: first, that models of individual treatment effects would reveal that benefit from intensive blood pressure therapy is proportional to baseline risk; and second, that a machine learning approach designed to predict heterogeneous treatment effects-the X-learner meta-algorithm-is equivalent to a conventional logistic regression approach., Methods and Results: We compared conventional logistic regression to the X-learner approach for prediction of 3-year cardiovascular disease event risk reduction from intensive (target systolic blood pressure <120 mm Hg) versus standard (target <140 mm Hg) blood pressure treatment, using individual participant data from the SPRINT (Systolic Blood Pressure Intervention Trial; N=9361) and ACCORD BP (Action to Control Cardiovascular Risk in Diabetes Blood Pressure; N=4733) trials. Each model incorporated 17 covariates, an indicator for treatment arm, and interaction terms between covariates and treatment. Logistic regression had lower C statistic for benefit than the X-learner (0.51 [95% CI, 0.49-0.53] versus 0.60 [95% CI, 0.58-0.63], respectively). Following the logistic regression's recommendation for individualized therapy produced restricted mean time until cardiovascular disease event of 1065.47 days (95% CI, 1061.04-1069.35), while following the X-learner's recommendation improved mean time until cardiovascular disease event to 1068.71 days (95% CI, 1065.42-1072.08). Calibration was worse for logistic regression; it over-estimated ARR attributable to intensive treatment (slope between predicted and observed ARR of 0.73 [95% CI, 0.30-1.14] versus 1.06 [95% CI, 0.74-1.32] for the X-learner, compared with the ideal of 1). Predicted ARRs using logistic regression were generally proportional to baseline pretreatment cardiovascular risk, whereas the X-learner observed-correctly-that individual treatment effects were often not proportional to baseline risk., Conclusions: Predictions for individual treatment effects from trial data reveal that patients may experience ARRs not simply proportional to baseline cardiovascular disease risk. Machine learning methods may improve discrimination and calibration of individualized treatment effect estimates from clinical trial data., Clinical Trial Registration: URL: https://www.clinicaltrials.gov . Unique identifiers: NCT01206062; NCT00000620.
- Published
- 2019
- Full Text
- View/download PDF
13. Prognostic Value of Cardiovascular Disease Risk Factors Measured in the First-Trimester on the Severity of Preeclampsia.
- Author
-
Cheng PJ, Huang SY, Su SY, Hsiao CH, Peng HH, and Duan T
- Subjects
- Adult, Biomarkers blood, C-Reactive Protein analysis, Case-Control Studies, Female, Fetal Growth Retardation blood, Homocysteine blood, Humans, Predictive Value of Tests, Pregnancy, Prospective Studies, ROC Curve, Risk Factors, Cardiovascular Diseases blood, Pre-Eclampsia blood, Pregnancy Trimester, First blood, Severity of Illness Index
- Abstract
Recent studies have suggested that preeclampsia and cardiovascular disease may share common mechanisms. The purpose of this prospective nested case-controlled study was to characterize a variety of cardiovascular disease risk factors measured during the first trimester of pregnancy in predicting subsequent outcomes and the severity of preeclampsia.We ascertained the severity of preeclampsia at the onset of the disease, and the presence of intrauterine growth restriction (IUGR). We compared first trimester maternal serum cardiovascular disease risk factors in preeclampsia subjects versus normal pregnancies, early-onset versus late-onset preeclampsia, and preeclampsia with IUGR versus without IUGR. To identify the prognostic value of independent predictors on the severity of preeclampsia, we calculated the area under the receiver operating characteristics curve (AUC) using logistic regression analysis.There were 134 cases of preeclampsia and 150 uncomplicated pregnancies, and preeclampsia cases were classified as early-onset (53 cases) or late-onset (81 cases), or as with IUGR (44 cases) or without IUGR (90 cases). Among the cardiovascular disease risk factors, maternal serum high-sensitive C-reactive protein (hsCRP) and homocysteine were predictors of both early-onset preeclampsia and preeclampsia with IUGR. For the detection of early onset preeclampsia or preeclampsia with IUGR, the AUC for the combination model (0.943 and 0.952, respectively) was significantly higher than with serum hsCRP or serum homocysteine only.Patients with preeclampsia can be subdivided into different severities according to time of onset and fetal weight. Cardiovascular risk factors distinguish a subgroup of these patients.
- Published
- 2016
- Full Text
- View/download PDF
14. Endoscopic Incision for the Treatment of Refractory Esophageal Anastomotic Strictures in Children.
- Author
-
Tan Y, Zhang J, Zhou J, Duan T, and Liu D
- Subjects
- Anastomosis, Surgical adverse effects, Child, Child, Preschool, Deglutition Disorders etiology, Deglutition Disorders surgery, Esophageal Stenosis etiology, Female, Humans, Male, Operative Time, Recurrence, Retrospective Studies, Stents, Treatment Outcome, Esophageal Atresia surgery, Esophageal Stenosis surgery, Esophagoscopy methods, Esophagus surgery
- Abstract
Objectives: The aim of the present study was to assess the safety and efficacy of endoscopic incision (EI) for the treatment of refractory anastomotic esophageal strictures in pediatric patients., Methods: We retrospectively reviewed the medical records of pediatric patients with refractory anastomotic strictures after surgical repair of esophageal atresia who underwent ≥3 sessions of endoscopic treatments (dilation and/or stenting). They were treated with EI alone or together with esophageal stenting. Efficacy and safety were evaluated during periodical follow-up., Results: All of the 7 children received the procedure successfully with the operation time of 15 to 60 minutes. Four of them received EI alone, whereas the other 3 received EI with esophageal stenting (EIES). The symptoms remitted in all of the patients, and the dysphagia score decreased from 3-4 to 0-1 during follow-up from 1 to 21 months. The average diameter of stricture was enlarged from 3 mm (range 2-5 mm) to 10.6 mm (range 8-12 mm). One patient suffered from chest pain, which resolved within 3 days. Patient 1 had recurrence 11 months after EIES, and patient 6 had recurrence 3 months after EI. They all underwent an additional EI to maintain patency. No severe complications were observed during operation and periodical follow-up., Conclusions: EI is safe and appears effective for refractory esophageal anastomotic strictures in children in the short term. Large comparative studies are warranted to further confirm our findings. The long-term follow-up is necessary for assessing the long-term efficacy of the new technique.
- Published
- 2015
- Full Text
- View/download PDF
15. A comparison of remifentanil parturient-controlled intravenous analgesia with epidural analgesia: a meta-analysis of randomized controlled trials.
- Author
-
Liu ZQ, Chen XB, Li HB, Qiu MT, and Duan T
- Subjects
- Female, Humans, Labor Pain diagnosis, Pregnancy, Remifentanil, Analgesia, Epidural methods, Analgesia, Patient-Controlled methods, Anesthetics, Intravenous administration & dosage, Labor Pain drug therapy, Piperidines administration & dosage, Randomized Controlled Trials as Topic methods
- Abstract
Background: Epidural analgesia is generally accepted as the most effective form of pain relief during labor. Remifentanil patient-controlled IV analgesia (PCIA), which is less invasive than epidural analgesia, may be an attractive alternative. In this meta-analysis, we compared the efficacy and safety of the 2 analgesic techniques for labor pain., Methods: Databases of PubMed, EMBASE, and Cochrane Library were searched independently by 2 reviewers to retrieve eligible randomized controlled clinical trials. The primary end points were pain scores at 1 and 2 hours, and the secondary end points were nausea, vomiting, pruritus, and umbilical artery pH values. Mean difference (MD) or risk ratio with 95% confidence intervals (CIs) were calculated for each end point. GRADE profiler was applied to assess the quality of evidence., Results: Five eligible trials were retrieved and analyzed. We found that parturients with remifentanil PCIA had higher visual analog scale (10-cm scale) pain scores than those who received epidural analgesia at 1 hour (MD = 1.9 cm; 95% CI, 0.5-3.3; I = 94%) and 2 hours (MD = 3.0 cm; 95% CI, 0.7-5.2; I = 89%) after initiation of analgesia. There was no statistical difference between epidural analgesia and remifentanil PCIA in the incidence of nausea, vomiting, pruritus, or umbilical artery pH values. However, the CIs are quite wide and contain clinically significant differences. According to GRADE profiler, most end points had moderate quality except that pain scores at 1 hour were of low quality., Conclusions: This meta-analysis suggests that remifentanil PCIA is not superior to epidural analgesia in analgesic efficacy during labor. Given the wide CIs of the pooled results for secondary maternal and neonatal outcomes, definite conclusions cannot be drawn for those outcomes. Further studies are still warranted to validate these conclusions.
- Published
- 2014
- Full Text
- View/download PDF
16. In reply.
- Author
-
Liu X, Duan T, Chang Q, He J, Chen M, and Zhang L
- Subjects
- Female, Humans, Pregnancy, Massage, Postpartum Hemorrhage prevention & control, Uterus physiology
- Published
- 2014
- Full Text
- View/download PDF
17. Uterine massage to reduce blood loss after vaginal delivery: a randomized controlled trial.
- Author
-
Chen M, Chang Q, Duan T, He J, Zhang L, and Liu X
- Subjects
- Adult, Delivery, Obstetric, Female, Humans, Parturition, Pregnancy, Massage, Postpartum Hemorrhage prevention & control, Uterus physiology
- Abstract
Objective: To evaluate whether sustained transabdominal uterine massage can reduce blood loss after vaginal delivery., Methods: In this multicenter randomized controlled trial, eligible women who had delivered vaginally were randomly assigned to receive 10 units oxytocin intramuscularly immediately after delivery of the shoulder plus 30 minutes of sustained transabdominal uterine massage after delivery of the placenta or to 10 units oxytocin intramuscularly alone. The primary outcome was blood loss of 400 mL or more in the 2 hours after delivery of the neonate. Secondary outcomes included blood loss of 1,000 mL or more, blood loss in the 2 hours after delivery, use of therapeutic uterotonics or other hemostatic procedures, hemoglobin of lower than 80 g/L before discharge, and need for blood transfusion. Analysis was by intent to treat. With a one-sided α of 0.05 and a power of 0.8, a sample size of 1,061 women per group was calculated to detect a 3% absolute decrease in the primary outcome., Results: Of 2,340 eligible women, 1,170 were randomized to oxytocin plus uterine massage and 1,170 to the oxytocin-only group. Baseline characteristics were similar in both groups. The incidence of blood loss of 400 mL or more in the 2 hours after delivery was not significantly different between the two groups (143/1,170 [12.2%] compared with 144/1,170 [12.3%]; relative risk 0.99, 95% confidence interval 0.88-1.13) according to intent-to-treat analysis with a power of more than 0.8. No significant differences were found in the secondary outcomes., Conclusion: In patients delivered vaginally, transabdominal uterine massage after delivery of the placenta in addition to oxytocin does not reduce blood loss when compared with administration of oxytocin alone., Clinical Trial Registration: Chinese Clinical Trial Registry, www.chictr.org, ChiCTR-TRC-11001763., Level of Evidence: I.
- Published
- 2013
- Full Text
- View/download PDF
18. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies).
- Author
-
Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH, Lang P, Larsen CP, Mancilla-Urrea E, Pestana JM, Block A, Duan T, Glicklich A, Gujrathi S, and Vincenti F
- Subjects
- Abatacept, Adult, Aged, Blood Glucose metabolism, Blood Pressure drug effects, Cardiovascular Diseases physiopathology, Cardiovascular Diseases prevention & control, Diabetes Mellitus blood, Diabetes Mellitus prevention & control, Female, Humans, Lipids blood, Male, Middle Aged, Risk Factors, Cardiovascular Diseases etiology, Cyclosporine adverse effects, Cyclosporine therapeutic use, Diabetes Mellitus etiology, Immunoconjugates adverse effects, Immunoconjugates therapeutic use, Immunosuppressive Agents adverse effects, Immunosuppressive Agents therapeutic use, Kidney Transplantation adverse effects
- Abstract
Background: Cardiovascular disease, the most common cause of death with a functioning graft among kidney transplant recipients, can be exacerbated by immunosuppressive drugs, particularly the calcineurin inhibitors. Belatacept, a selective co-stimulation blocker, may provide a better cardiovascular/metabolic risk profile than current immunosuppressants., Methods: Cardiovascular and metabolic endpoints from two Phase III studies (BENEFIT and BENEFIT-EXT) of belatacept-based regimens in kidney transplant recipients were assessed at month 12. Each study assessed belatacept in more intensive (MI) and less intensive (LI) regimens versus cyclosporine A (CsA). These secondary endpoints included changes in blood pressure, changes in serum lipids, and the incidence of new-onset diabetes after transplant (NODAT)., Results: A total of 1209 patients were randomized and transplanted across the two studies. Mean systolic blood pressure was 6 to 9 mm Hg lower and mean diastolic blood pressure was 3 to 4 mm Hg lower in the MI and LI groups versus CsA (P ≤ 0.002) across both studies at month 12. Non-HDL cholesterol was lower in the belatacept groups versus CsA (P<0.01 MI or LI vs. CsA in each study). Serum triglycerides were lower in the belatacept groups versus CsA (P<0.02 MI or LI vs. CsA in each study). NODAT occurred less often in the belatacept groups versus CsA in a prespecified pooled analysis (P<0.05 MI or LI vs. CsA)., Conclusions: At month 12, belatacept regimens were associated with better cardiovascular and metabolic risk profiles, with lower blood pressure and serum lipids and less NODAT versus CsA. The overall profile of belatacept will continue to be assessed over the 3-year trials.
- Published
- 2011
- Full Text
- View/download PDF
19. Assisted reproductive technology and placenta-mediated adverse pregnancy outcomes.
- Author
-
Sun LM, Walker MC, Cao HL, Yang Q, Duan T, and Kingdom JCP
- Subjects
- Adult, Case-Control Studies, Female, Humans, Infant, Newborn, Infant, Small for Gestational Age, Odds Ratio, Pregnancy, Abruptio Placentae etiology, Fertilization in Vitro adverse effects, Insemination, Artificial adverse effects, Pre-Eclampsia etiology, Stillbirth
- Abstract
Objective: To estimate whether the use of specific types of assisted reproductive technology (ART) is associated with an increased risk of placenta-mediated pregnancy complications, which include preeclampsia, stillbirth, small for gestational age at birth, and placental abruption., Methods: A population-based retrospective cohort study was conducted on singleton pregnancies conceived by different types of ART based on the 2004-2007 Ontario Niday Perinatal Database. Patients with fetal anomalies and maternal health problems were excluded as important confounders. Three exposed groups were created by the subtype of ART, including in vitro fertilization with or without intracytoplasmic sperm injection, intrauterine insemination, and ovulation induction. The nonexposed groups were the singleton pregnancies conceived naturally. For each exposed woman, four women from the nonexposed group were randomly matched by maternal age and parity., Results: There were 2,118 exposed participants and 8,420 matched nonexposed participants in the study. The sample size provided 80% power for a relative risk of 2.0 of placenta-mediated adverse pregnancy outcomes with ART. After adjustment of potential confounders, including smoking, delivery hospital level, initiating time of prenatal care, average neighborhood income, fetal sex, and previous cesarean delivery, there was no association observed between different types of ART groups and the composite of placenta-mediated pregnancy complications. Intrauterine insemination was associated with a significantly increased risk of preeclampsia (12 [2.67%] odds ratio 2.2, 95% confidence interval 1.04-5.04) compared with the corresponding control group (23 [1.29%])., Conclusion: Assisted reproductive technology is not associated with an increased risk of the composite outcome of placenta-mediated pregnancy complications among singleton pregnancies., Level of Evidence: II.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.